Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Christine Berni Silverstein Sells 13,093 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Christine Berni Silverstein sold 13,093 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $76,724.98. Following the transaction, the director directly owned 120,479 shares of the company's stock, valued at $706,006.94. This represents a 9.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Abeona Therapeutics Price Performance

NASDAQ:ABEO traded down $0.11 during trading hours on Friday, hitting $5.74. The stock had a trading volume of 774,254 shares, compared to its average volume of 701,305. The company has a 50 day simple moving average of $6.01 and a two-hundred day simple moving average of $5.57. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.90 and a quick ratio of 4.90. Abeona Therapeutics Inc. has a one year low of $3.93 and a one year high of $7.32. The firm has a market capitalization of $293.66 million, a price-to-earnings ratio of -4.52 and a beta of 1.51.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.11. Research analysts forecast that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ABEO. Adage Capital Partners GP L.L.C. boosted its holdings in Abeona Therapeutics by 20.1% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock valued at $21,736,000 after purchasing an additional 652,366 shares during the period. Western Standard LLC boosted its holdings in Abeona Therapeutics by 22.8% in the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock valued at $11,610,000 after purchasing an additional 386,321 shares during the period. Jane Street Group LLC boosted its holdings in Abeona Therapeutics by 894.8% in the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock valued at $732,000 after purchasing an additional 118,262 shares during the period. 683 Capital Management LLC boosted its holdings in Abeona Therapeutics by 17.3% in the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company's stock valued at $4,411,000 after purchasing an additional 116,845 shares during the period. Finally, Newtyn Management LLC boosted its holdings in Abeona Therapeutics by 26.3% in the 1st quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock valued at $2,285,000 after purchasing an additional 100,000 shares during the period. 80.56% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ABEO. Stifel Nicolaus reduced their target price on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, May 16th. HC Wainwright increased their target price on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. Wall Street Zen downgraded shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Finally, Oppenheimer assumed coverage on shares of Abeona Therapeutics in a report on Monday, June 2nd. They issued an "outperform" rating and a $19.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, Abeona Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $19.25.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.